🟢 Neurosense Therapeutics Ltd is trading 10.4% up on Japanese Patent Grant for its ALS drug PrimeC

Neurosense Therapeutics Ltd is trading 10.4% up at $0.83 in pre-market action after the company announced a key patent grant in Japan.

• The Japan Patent Office has issued a patent for the company's lead drug candidate, PrimeC, a treatment for amyotrophic lateral sclerosis (ALS).
• The patent, titled "Compositions comprising ciprofloxacin and celecoxib," provides intellectual property protection for PrimeC in the key Japanese pharmaceutical market through 2042.
• This news provides a clear fundamental catalyst for the stock's rally, validating the significant pre-market move.